Introduction to Sotoracib (AMG510)

Sotorasib (AMG510), commonly known as Sotorasib, is an innovative drug that is considered a breakthrough in the treatment of lung cancer. As a small molecule targeted drug, sotoraxib's mechanism of action mainly targets KRAS gene mutations in tumor cells, especially G12C mutations.

KRAS gene mutations are among the most common mutations in many cancers, including lung cancer. This mutation causes the abnormal activation of KRAS protein and promotes the abnormal proliferation and survival of tumor cells. Sotoracib specifically binds to the KRAS G12C protein and inhibits its activity, thereby blocking the proliferation signaling of tumor cells and inhibiting the growth and spread of tumors.

Clinical trials have shown that sotoraxib exhibits significant anti-tumor effects in KRAS G12C mutated lung cancer patients. Some patients have observed tumor shrinkage or stabilization, and in some cases, tumor burden is reduced or even completely eliminated. Compared with traditional chemotherapy and radiotherapy, sotoraxib has a more direct and effective targeting effect, while also having good safety and tolerability.

The success of sotoracib represents a major advancement in the field of lung cancer treatment, filling the gap in the previous treatment of KRAS mutated tumors. It provides new ideas and methods for tumor treatment and is expected to become one of the standard treatment options in the treatment of lung cancer in the future. With further research into its mechanism of action and efficacy, sotoraxib may also show broader promise in the treatment of other cancer types.